Reduced glomerular function and prevalence of gout: NHANES 2009-10
about
Filipino gout: a reviewChronic kidney disease as a risk factor for incident gout among men and women: retrospective cohort study using data from the Framingham Heart Study.Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies.Gout after living kidney donation: correlations with demographic traits and renal complicationsIndividuals With Type 2 Diabetes Mellitus Are at an Increased Risk of Gout But This Is Not Due to Diabetes: A Population-Based Cohort Study.Association of uric acid with metabolic syndrome in men, premenopausal women and postmenopausal womenLong-term medical risks to the living kidney donor.KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors.Hyperuricemia, the kidneys, and the spectrum of associated diseases: a narrative review.Management of Gout and Hyperuricemia in CKD.Insight into rheumatological cause and effect through the use of Mendelian randomization.Recent advances in understanding and managing goutImpact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment.The prevalence of gout in an urban area of Izmir, Turkey: a population-based epidemiological study.The 3-Year Incidence of Gout in Elderly Patients with CKD.The potential renoprotection of xanthine oxidase inhibitors: Febuxostat versus allopurinol.Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study.Chronic kidney disease and the risk of incident gout among middle-aged men: a seven-year prospective observational study.Major Cardiovascular Events in Patients with Gout and Associated Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating a Xanthine Oxidase Inhibitor.Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea.Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics.Temporal trends in hyperuricaemia in the Irish health system from 2006-2014: A cohort study.Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.Determinants of hyperuricemia in non-dialysed chronic kidney disease patients in three hospitals in Cameroon.Langfassung zur S2e-Leitlinie Gichtarthritis (fachärztlich)
P2860
Q27027299-D66E505C-39A5-45C9-B05D-CF56CDA77BD4Q30930909-F36D3BEA-BACC-42A1-BC6D-260952A23E25Q35503271-D977ADCC-1866-4F00-B871-E542269190BCQ35908386-DC42CB9E-8915-4414-9C3A-A1CA0954B902Q36195260-2EE7F5CD-EBB5-46FF-9276-748C20812279Q37703252-43F94734-A0D9-449F-B925-02631DD72995Q38458930-65C6EDD6-541F-457D-8497-056DF3019EA9Q38652031-2EF9683E-80A3-4223-8BD7-C9DCEFE0AF06Q38810539-C35BBB4D-30D2-4E1C-A8C9-9551F663EC10Q38812962-623B8CB8-5B30-4BFD-87D1-65A91BEE1442Q38895577-FE68BDB5-6E65-491E-93D3-C8661110B044Q39207801-85CEAE7D-D33E-4F4F-9865-0339802AB89FQ39984416-4FD6EADB-1CB6-49C1-A87A-B1590F5E6C31Q40171932-42F03CC5-1F61-4DA4-AA4B-D4748134476CQ40353089-8C276323-780C-49DA-ADDC-EDEC8143696FQ42356139-CC8A313E-36D2-4234-B99C-080BB2E2B31DQ45065392-2B14421D-2D34-4380-9023-EFB1F3F7C70FQ46070363-74377B05-9C5E-4B95-8B50-185983F6F86EQ47150749-60E766E2-05C4-4A10-B91B-B2BCE5F5860AQ51067041-0CB6AA32-7AD9-4107-9386-74F9DEA19274Q51746631-5DCAF8D6-4314-488F-B7E7-6E8A8146040DQ55263622-9933A8B9-D6C5-4EB8-98AE-3F72F924721AQ55284599-CA17B128-B61E-489E-9A7A-473AC67A4BE1Q55564382-D3CEAE4A-6625-4571-99F0-3E47130494E6Q56637250-1340BAE8-6B20-44A9-93E6-2BF6482CACA4
P2860
Reduced glomerular function and prevalence of gout: NHANES 2009-10
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Reduced glomerular function and prevalence of gout: NHANES 2009-10
@ast
Reduced glomerular function and prevalence of gout: NHANES 2009-10
@en
Reduced glomerular function and prevalence of gout: NHANES 2009-10
@nl
type
label
Reduced glomerular function and prevalence of gout: NHANES 2009-10
@ast
Reduced glomerular function and prevalence of gout: NHANES 2009-10
@en
Reduced glomerular function and prevalence of gout: NHANES 2009-10
@nl
prefLabel
Reduced glomerular function and prevalence of gout: NHANES 2009-10
@ast
Reduced glomerular function and prevalence of gout: NHANES 2009-10
@en
Reduced glomerular function and prevalence of gout: NHANES 2009-10
@nl
P2860
P1433
P1476
Reduced glomerular function and prevalence of gout: NHANES 2009-10
@en
P2093
Eswar Krishnan
P2860
P304
P356
10.1371/JOURNAL.PONE.0050046
P407
P577
2012-11-27T00:00:00Z